Overview
Abata Therapeutics develops therapies for autoimmune diseases, with a focus on type 1 diabetes, using regulatory T cell (Treg) therapy. Its lead product, ABA 201, is a Treg cell therapy for patients with type 1 diabetes who still have some beta cell function and is in IND-enabling studies with plans to begin clinical trials by 2025. The treatment works by using regulatory T cells to dampen autoimmune attacks and help preserve insulin-producing beta cells, supported by ElevateBio for process development and scalable manufacturing. The company differentiates itself through its focused autoimmune niche, science-driven Treg approach, and strategic partnerships, aiming to bring these therapies to patients via R&D, grants, collaborations, and future sales.
Work here?Claim your company
Simplify's take
What believers are saying
- National MS Society listed NCT06566261 in October 2026, confirming ongoing human enrollment.
- Abata appointed Joanne Beck CTO in September 2024 and Leonard Dragone CMO earlier.
- Simplify reports $205.3 million total funding, supporting runway through early clinical readouts.
What critics are saying
- ABA-101 remains Phase I and active not recruiting; efficacy evidence is still absent.
- Abata’s November 2026 website deprovisioning signals corporate distress and possible shutdown timeline.
- A negative NCT06566261 safety signal would kill the platform before 2027 financing.
What makes Abata Therapeutics unique
- ABA-101 targets CNS-compartmentalized inflammation in progressive MS using antigen-specific Tregs.
- Bristol Myers Squibb invested in August 2024, validating Abata’s platform and syndicate.
- ElevateBio BaseCamp manufacturing expertise gives Abata cell-process scale other Treg startups lack.
Help us improve and share your feedback! Did you find this helpful?
